Welcome to the Novel Therapies for Type 2 Diabetes and Obesity Summit
Advance Therapies to Rival Bariatric Surgery
Identify Disease-Modifying Targets to Sustainably Transform Glycaemic Control
Manage Diabetic Complications to Reduce Mortality in Metabolic Disorders
The wave of breakthrough therapies in drug-based management of obesity has triggered a renaissance in metabolic disorders. As GLP-1 receptor agonists establish a new gold standard in weight-loss and first-in-class therapies demonstrate additional benefit in type 2 diabetes, stakeholders are flooding in to redefine the metabolic landscape.
Uniting industry experts dedicated to accelerating the frontier of disease-modifying therapeutics beyond the current standard of care, the Novel Therapies for Type 2 Diabetes & Obesity Summit is the definitive industry forum sharing cross-industry insight to treat an exponentially growing patient population.
From elucidating body weight set points to establish opportunities for therapeutic intervention, to demonstrating metabolic effect in diabetes to treat interrelated cardiorenal comorbidities, join industry experts including Novo Nordisk, Eli Lilly & Company, Altimmune, Regeneron, Boehringer Ingelheim, Amgen and more to navigate the pathway to regulatory approval for big pharma and smaller biotech.
World-Class Speaker Faculty Includes:
Medical Vice President, Global & US Therapeutic Area Head, Cardiovascular & Metabolism
Head Of Clinical Research & Next Generation Incretins
Eli Lilly & Company
Chief Scientific Officer
President & Chief Executive Officer
Vice President, Cardiovascular & Metabolism Therapeutics
“This meeting allows for dialogue and collaboration between groups that all want the same thing: eradicate the greatest threats to metabolic health in the modern age.”
Siddique Abbasi, Executive Medical Director & Global Development Lead, Amgen
“An opportunity to engage in a robust scientific discussion with the companies leading the way towards effective therapeutic strategies for obesity and related metabolic diseases.”
Randy Seeley, Henry King Ransom Professor of Surgery, University of Michigan
“These meetings bring together stakeholders from multiple backgrounds allowing the type of interactions that are needed for researchers, drug developers, and policy makers to establish and develop new pathways to improve healthcare.”
Jerry Colca, Chief Scientific Officer, Cirius Therapeutics